<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:08:53Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8351379" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8351379</identifier>
        <datestamp>2021-08-15</datestamp>
        <setSpec>ancltransneuro</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" id="acn351421" xml:lang="en" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Ann Clin Transl Neurol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Ann Clin Transl Neurol</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2328-9503</journal-id>
              <journal-id journal-id-type="publisher-id">ACN3</journal-id>
              <journal-title-group>
                <journal-title>Annals of Clinical and Translational Neurology</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2328-9503</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8351379</article-id>
              <article-id pub-id-type="pmcid">PMC8351379</article-id>
              <article-id pub-id-type="pmc-uid">8351379</article-id>
              <article-id pub-id-type="pmid">34275209</article-id>
              <article-id pub-id-type="pmid">34275209</article-id>
              <article-id pub-id-type="doi">10.1002/acn3.51421</article-id>
              <article-id pub-id-type="publisher-id">ACN351421</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effects of simvastatin on white matter integrity in healthy middle‐aged adults</article-title>
                <alt-title alt-title-type="right-running-head">Effects of Simvastatin on White Matter Integrity</alt-title>
                <alt-title alt-title-type="left-running-head">VOGT <italic toggle="no">et al</italic>.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="acn351421-cr-0001" contrib-type="author">
                  <name>
                    <surname>Vogt</surname>
                    <given-names>Nicholas M.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2334-1495</contrib-id>
                  <xref rid="acn351421-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acn351421-cr-0002" contrib-type="author">
                  <name>
                    <surname>Hunt</surname>
                    <given-names>Jack F. V.</given-names>
                  </name>
                  <xref rid="acn351421-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acn351421-cr-0003" contrib-type="author">
                  <name>
                    <surname>Ma</surname>
                    <given-names>Yue</given-names>
                  </name>
                  <xref rid="acn351421-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acn351421-cr-0004" contrib-type="author">
                  <name>
                    <surname>Van Hulle</surname>
                    <given-names>Carol A.</given-names>
                  </name>
                  <xref rid="acn351421-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acn351421-cr-0005" contrib-type="author">
                  <name>
                    <surname>Adluru</surname>
                    <given-names>Nagesh</given-names>
                  </name>
                  <xref rid="acn351421-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="acn351421-cr-0006" contrib-type="author">
                  <name>
                    <surname>Chappell</surname>
                    <given-names>Richard J.</given-names>
                  </name>
                  <xref rid="acn351421-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="acn351421-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="acn351421-cr-0007" contrib-type="author">
                  <name>
                    <surname>Lazar</surname>
                    <given-names>Karen K.</given-names>
                  </name>
                  <xref rid="acn351421-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acn351421-cr-0008" contrib-type="author">
                  <name>
                    <surname>Jacobson</surname>
                    <given-names>Laura E</given-names>
                  </name>
                  <xref rid="acn351421-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acn351421-cr-0009" contrib-type="author">
                  <name>
                    <surname>Austin</surname>
                    <given-names>Benjamin P.</given-names>
                  </name>
                  <xref rid="acn351421-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acn351421-cr-0010" contrib-type="author">
                  <name>
                    <surname>Asthana</surname>
                    <given-names>Sanjay</given-names>
                  </name>
                  <xref rid="acn351421-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="acn351421-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="acn351421-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="acn351421-cr-0011" contrib-type="author">
                  <name>
                    <surname>Johnson</surname>
                    <given-names>Sterling C.</given-names>
                  </name>
                  <xref rid="acn351421-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="acn351421-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="acn351421-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="acn351421-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="acn351421-cr-0012" contrib-type="author">
                  <name>
                    <surname>Bendlin</surname>
                    <given-names>Barbara B.</given-names>
                  </name>
                  <xref rid="acn351421-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="acn351421-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="acn351421-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="acn351421-cr-0013" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Carlsson</surname>
                    <given-names>Cynthia M.</given-names>
                  </name>
                  <xref rid="acn351421-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="acn351421-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="acn351421-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="acn351421-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <address>
                    <email>nvogt@wisc.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="acn351421-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Wisconsin Alzheimer’s Disease Research Center</named-content>
                <institution>University of Wisconsin School of Medicine and Public Health</institution>
                <city>Madison</city>
                <named-content content-type="country-part">Wisconsin</named-content>
              </aff>
              <aff id="acn351421-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Waisman Laboratory for Brain Imaging and Behavior</named-content>
                <named-content content-type="organisation-division">Waisman Center</named-content>
                <institution>University of Wisconsin‐Madison</institution>
                <city>Madison</city>
                <named-content content-type="country-part">Wisconsin</named-content>
              </aff>
              <aff id="acn351421-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Biostatistics and Medical Informatics</named-content>
                <institution>University of Wisconsin School of Medicine and Public Health</institution>
                <city>Madison</city>
                <named-content content-type="country-part">Wisconsin</named-content>
              </aff>
              <aff id="acn351421-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Geriatric Research Education and Clinical Center</named-content>
                <institution>William S. Middleton Memorial Veterans Hospital</institution>
                <city>Madison</city>
                <named-content content-type="country-part">Wisconsin</named-content>
              </aff>
              <aff id="acn351421-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Geriatrics Division</named-content>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>University of Wisconsin School of Medicine and Public Health</institution>
                <city>Madison</city>
                <named-content content-type="country-part">Wisconsin</named-content>
              </aff>
              <aff id="acn351421-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Wisconsin Alzheimer’s Institute</named-content>
                <institution>University of Wisconsin School of Medicine and Public Health</institution>
                <city>Madison</city>
                <named-content content-type="country-part">Wisconsin</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Cynthia M. Carlsson, Wisconsin Alzheimer’s Disease Research Center (ADRC), 600 Highland Ave, Madison, WI 53792. Tel: (608) 256‐1901; E‐mail: <email>cmc@medicine.wisc.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>18</day>
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <volume>8</volume>
              <issue seq="90">8</issue>
              <issue-id pub-id-type="doi">10.1002/acn3.v8.8</issue-id>
              <fpage>1656</fpage>
              <lpage>1667</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>22</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
                <date date-type="received">
                  <day>27</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>23</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2021 American Neurological Association-->
                <copyright-statement content-type="article-copyright">© 2021 The Authors. <italic toggle="yes">Annals of Clinical and Translational Neurology</italic> published by Wiley Periodicals LLC on behalf of American Neurological Association</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:ACN3-8-1656.pdf"/>
              <abstract id="acn351421-abs-0001">
                <title>Abstract</title>
                <sec id="acn351421-sec-0001">
                  <title>Background</title>
                  <p>The brain is the most cholesterol‐rich organ and myelin contains 70% of total brain cholesterol. Statins are potent cholesterol‐lowing medications used by millions of adults for prevention of vascular disease, yet the effect of statins on cholesterol‐rich brain white matter (WM) is largely unknown.</p>
                </sec>
                <sec id="acn351421-sec-0002">
                  <title>Methods</title>
                  <p>We used longitudinal neuroimaging data acquired from 73 healthy, cognitively unimpaired, statin‐naïve, middle‐aged adults during an 18‐month randomized controlled trial of simvastatin 40 mg daily (<italic toggle="yes">n</italic> = 35) or matching placebo (<italic toggle="yes">n</italic> = 38). ANCOVA models (covariates: age, sex, <italic toggle="yes">APOE</italic>‐ɛ4) tested the effect of treatment group on percent change in WM, gray matter (GM), and WM hyperintensity (WMH) neuroimaging measures at each study visit. Mediation analysis tested the indirect effects of simvastatin on WM microstructure through change in serum total cholesterol levels.</p>
                </sec>
                <sec id="acn351421-sec-0003">
                  <title>Results</title>
                  <p>At 18 months, the simvastatin group showed a significant preservation in global WM fractional anisotropy (β = 0.88%, 95% CI 0.27 to 1.50, <italic toggle="yes">P</italic> = 0.005), radial diffusivity (β<italic toggle="yes"> = </italic>−1.10%, 95% CI −2.13 to −0.06, <italic toggle="yes">P</italic> = 0.039), and WM volume (β<italic toggle="yes"> = </italic>0.72%, 95% CI 0.13 to 1.32, <italic toggle="yes">P</italic> = 0.018) relative to the placebo group. There was no significant effect of simvastatin on GM or WMH volume. Change in serum total cholesterol mediated approximately 30% of the effect of simvastatin on WM microstructure.</p>
                </sec>
                <sec id="acn351421-sec-0004">
                  <title>Conclusions</title>
                  <p>Simvastatin treatment in healthy, middle‐aged adults resulted in preserved WM microstructure and volume at 18 months. The partial mediation by serum cholesterol reduction suggests both peripheral and central mechanisms. Future studies are needed to determine whether these effects persist and translate to cognitive outcomes.</p>
                </sec>
                <sec id="acn351421-sec-0005">
                  <title>Trial Registration</title>
                  <p>NCT00939822 (ClinicalTrials.gov).</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institute on Aging
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000049</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>F30AG059346</award-id>
                  <award-id>P50AG033514</award-id>
                  <award-id>R01AG027161</award-id>
                  <award-id>R01AG031790</award-id>
                  <award-id>R01AG037639</award-id>
                </award-group>
                <funding-statement>This work was funded by <funding-source><institution-wrap><institution>National Institute on Aging
</institution><institution-id institution-id-type="doi">10.13039/100000049</institution-id></institution-wrap></funding-source> grants <award-id>F30AG059346</award-id>, <award-id>P50AG033514</award-id>, <award-id>R01AG027161</award-id>, <award-id>R01AG031790</award-id>, and <award-id>R01AG037639</award-id>.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="4"/>
                <table-count count="3"/>
                <page-count count="12"/>
                <word-count count="6779"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>August 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.4 mode:remove_FC converted:09.08.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <fn-group id="acn351421-ntgp-0001">
                <fn fn-type="funding" id="acn351421-note-0001">
                  <p>
                    <bold>Funding Information</bold>
                  </p>
                  <p>This work was supported by National Institutes of Health awards F30AG059346 (NMV), R01AG031790 (CMC), R01AG037639 (BBB), R01AG027161 (SCJ), and P50AG033514 (SA). Additional support from the Geriatric Research, Education, and Clinical Center of the William S. Middleton Memorial Veterans Hospital (Madison VA GRECC manuscript number 012‐2020).</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="acn351421-body-0001">
            <sec id="acn351421-sec-0006">
              <title>Introduction</title>
              <p>The brain is the most cholesterol‐rich organ and contains nearly a quarter of total body cholesterol.<xref rid="acn351421-bib-0001" ref-type="bibr"><sup>1</sup></xref> Within the brain, cholesterol exists in two primary pools—approximately 70% of brain cholesterol is found in myelin sheaths and the remainder is located in the cell membranes of neurons and astrocytes.<xref rid="acn351421-bib-0002" ref-type="bibr"><sup>2</sup></xref> Cholesterol is required for myelination<xref rid="acn351421-bib-0003" ref-type="bibr"><sup>3</sup></xref> and contributes to the insulating properties of mature myelin by reducing ion permeability.<xref rid="acn351421-bib-0001" ref-type="bibr"><sup>1</sup></xref> Cholesterol homeostasis in the brain is independent of peripheral cholesterol metabolism and is maintained by complex regulatory mechanisms. Because the blood–brain barrier (BBB) prevents uptake of peripheral cholesterol from circulating lipoproteins, essentially all brain cholesterol is synthesized <italic toggle="yes">de novo</italic>,<xref rid="acn351421-bib-0002" ref-type="bibr"><sup>2</sup></xref> with significantly greater production in glia than in neurons.<xref rid="acn351421-bib-0004" ref-type="bibr"><sup>4</sup></xref> Additionally, while cholesterol in peripheral tissues undergoes turnover every few days, brain cholesterol has an extremely long half‐life of 6 months to 5 years<xref rid="acn351421-bib-0005" ref-type="bibr"><sup>5</sup></xref> due to highly efficient recycling processes.</p>
              <p>Statins are potent cholesterol‐lowering medications used by millions of adults for the treatment of hypercholesterolemia and prevention of cardiovascular and cerebrovascular disease. By inhibiting HMG‐CoA reductase (the rate‐limiting enzyme in cholesterol synthesis), statins decrease cholesterol production and increase clearance of low‐density lipoprotein (LDL) particles, which results in a reduction in peripheral circulating cholesterol levels.<xref rid="acn351421-bib-0006" ref-type="bibr"><sup>6</sup></xref> Several statins (including simvastatin) can cross the BBB to enter the central nervous system (CNS), where they not only inhibit brain cholesterol synthesis, but also have pleotropic effects.<xref rid="acn351421-bib-0007" ref-type="bibr"><sup>7</sup></xref> Despite the widespread use of statins, it is largely unknown how these medications affect cholesterol‐rich white matter (WM) brain regions in humans.</p>
              <p>Diffusion tensor imaging (DTI) is an in vivo neuroimaging technique that has been widely used to study WM microstructure.<xref rid="acn351421-bib-0008" ref-type="bibr"><sup>8</sup></xref> By measuring the diffusion of water molecules within tissues, DTI provides quantitative information regarding alterations in WM integrity (e.g., axonal and myelin damage). A limited number of previous studies have attempted to assess the influence of statins on WM microstructure using DTI.<xref rid="acn351421-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="acn351421-bib-0010" ref-type="bibr"><sup>10</sup></xref> However, these studies have been observational in nature, and are potentially confounded by the statin‐exposed individuals having significantly elevated cardiovascular disease risk factors, which can also affect WM microstructure. Thus, causative effects of statins on WM microstructure remain to be determined.</p>
              <p>In this study, we took advantage of longitudinal neuroimaging data acquired during an 18‐month randomized controlled trial of simvastatin in healthy, statin‐naïve, cognitively unimpaired, middle‐aged adults. We tested the effect of simvastatin treatment on longitudinal global and regional WM microstructure (as measured by DTI metrics), as well as longitudinal WM volume (derived from conventional T1‐weighted MRI), and white matter hyperintensity (WMH) lesion volume. Additionally, to determine if the effects of simvastatin were specific to WM, we assessed the effect of simvastatin on longitudinal gray matter (GM) volume. Finally, in order to investigate potential causal mechanisms, we tested whether the effect of simvastatin on WM microstructure was mediated by changes in peripheral cholesterol levels.</p>
            </sec>
            <sec sec-type="methods" id="acn351421-sec-0007">
              <title>Methods</title>
              <sec id="acn351421-sec-0008">
                <title>Study design and participants</title>
                <p>This secondary analysis used data acquired from a prospective, double‐blind, randomized controlled trial designed to evaluate the effects of simvastatin on beta amyloid pathology as indexed by CSF biomarkers in healthy, cognitively unimpaired, middle‐aged (40–72 years old) adults with a parental family history of Alzheimer’s disease dementia (ClinicalTrial.gov identifier: NCT00939822).<xref rid="acn351421-bib-0011" ref-type="bibr"><sup>11</sup></xref> Main exclusion criteria included current use of cholesterol‐lowering medications, contraindication to use of statins, or history of known cardiovascular disease requiring use of statin (see Table <xref rid="acn351421-tbl-0001" ref-type="table">1</xref> for full eligibility criteria). In the original trial, there was no effect of simvastatin over 18 months on the primary endpoint of changes in CSF beta amyloid or secondary endpoints of changes in CSF soluble amyloid precursor protein or tau protein.</p>
                <table-wrap position="float" id="acn351421-tbl-0001" content-type="Table">
                  <label>Table 1</label>
                  <caption>
                    <p>Full eligibility criteria for study.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Inclusion criteria</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0001">
                            <list-item>
                              <p>Parental history of probable or definite Alzheimer’s disease dementia</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0002">
                            <list-item>
                              <p>Age 40–72 years</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Exclusion criteria</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0003">
                            <list-item>
                              <p>Dementia or mild cognitive impairment (MCI) on screening evaluation</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0004">
                            <list-item>
                              <p>Current use of cholesterol‐lowering medication</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0005">
                            <list-item>
                              <p>History of liver disease (cirrhosis, hepatitis, or elevation of AST or ALT &gt; 2 times upper limits of normal)</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0006">
                            <list-item>
                              <p>History of adverse reaction to statin drug</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0007">
                            <list-item>
                              <p>Elevated CK (&gt;2 times upper limit of normal)</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0008">
                            <list-item>
                              <p>Use of medications known to interact with statins, including: erythromycin, clarithromycin, digoxin, itraconazole, ketoconazole, fluconazole, nefazodone, cyclosporine, protease inhibitors, amiodarone, verapamil, warfarin, or investigational drug in another trial</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0009">
                            <list-item>
                              <p>Use of large quantities of grapefruit juice (&gt; 1 quart/day)</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0010">
                            <list-item>
                              <p>Elevated creatinine (&gt; 1.8 mg/dL at baseline)</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0011">
                            <list-item>
                              <p>Pregnancy</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0012">
                            <list-item>
                              <p>Previous history of lumbar spine surgery with contraindication to lumbar puncture</p>
                            </list-item>
                            <list-item>
                              <p>Contraindication to lumbar puncture due to use of warfarin or other anticoagulants</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0013">
                            <list-item>
                              <p>Claustrophobia requiring sedation for MRI</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0014">
                            <list-item>
                              <p>Pacemaker or other contraindication to Gd‐enhanced MRI</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0015">
                            <list-item>
                              <p>History of MI, significant arterial occlusive disease, DM, or stroke</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <list list-type="bullet" id="acn351421-list-0016">
                            <list-item>
                              <p>LDL‐C &gt; 160 mg/Dl and two or more CHD risk factors</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>Eligible participants underwent a screening visit and a total of 88 participants were randomly assigned to receive simvastatin (40 mg, daily) in the treatment group (<italic toggle="yes">n</italic> = 44), or matching placebo in the control group (<italic toggle="yes">n</italic> = 44) for 18 months (see Fig. <xref rid="acn351421-fig-0001" ref-type="fig">1</xref> for flowchart of trial enrollment and Supplemental Table <xref rid="acn351421-sup-0001" ref-type="supplementary-material">S1</xref> for participant characteristics of full original study population). Participants underwent fasting blood draw and MRI at baseline, 6‐, 12‐, and 18‐month study visits. A total of 73 participants (<italic toggle="yes">n</italic> = 38 placebo, <italic toggle="yes">n</italic> = 35 simvastatin) had complete neuroimaging data and were included in the current analyses. The University of Wisconsin Health Sciences Institutional Review Board approved all study procedures and all participants provided written informed consent. Data were collected from November 24, 2009 to September 17, 2013.</p>
                <fig position="float" fig-type="Figure" id="acn351421-fig-0001">
                  <label>Figure 1</label>
                  <caption>
                    <p>Flow diagram of study trial enrollment, randomization, treatment, and exclusion criteria for neuroimaging analyses.</p>
                  </caption>
                  <graphic xlink:href="ACN3-8-1656-g002" position="anchor" id="jats-graphic-1"/>
                </fig>
              </sec>
              <sec id="acn351421-sec-0009">
                <title>MRI acquisition details</title>
                <p>Diffusion‐weighted images were acquired using a spin‐echo, single‐shot, echo‐planar imaging pulse sequence (8 × <italic toggle="yes">b</italic> = 0 s/mm<sup>2</sup>, 40 × <italic toggle="yes">b</italic> = 1300 s/mm<sup>2</sup>; TR/TE = 8000/84.5 ms; flip angle = 90°; FOV = 240 mm; 96 × 96 acquisition matrix; 2.5 × 2.5 × 2.5 mm<sup>3</sup> isotropic voxel resolution). T1‐weighted structural images were acquired using a 3D inversion recovery prepared fast spoiled gradient‐echo FSPGR‐BRAVO sequence (TI = 450 ms; TR/TE = 8.1/3.2 ms; flip angle = 12°; FOV = 256 mm; 256 × 256 acquisition matrix; 1 × 1 × 1 mm<sup>3</sup> isotropic voxel resolution). T2‐weighted images were acquired using a 3D fluid‐attenuated inversion recovery (FLAIR) pulse sequence (TI = 1871 ms; TR/TE = 6000/122.3 ms; flip angle = 90°; FOV = 256 mm; 256 × 256 acquisition matrix; 1 × 1 × 1 mm<sup>3</sup> isotropic voxel resolution).</p>
              </sec>
              <sec id="acn351421-sec-0010">
                <title>MRI processing</title>
                <p>Diffusion‐weighted images were denoised,<xref rid="acn351421-bib-0012" ref-type="bibr"><sup>12</sup></xref> corrected for Gibbs ringing,<xref rid="acn351421-bib-0013" ref-type="bibr"><sup>13</sup></xref> and corrected for motion and eddy current distortions.<xref rid="acn351421-bib-0014" ref-type="bibr"><sup>14</sup></xref> DTI parameter maps (fractional anisotropy [FA], mean diffusivity [MD], radial diffusivity [RD], and axial diffusivity [AD]) were fit using Diffusion Imaging in Python (DIPY)<xref rid="acn351421-bib-0015" ref-type="bibr"><sup>15</sup></xref> and visually inspected prior to further processing. Mean DTI measures were extracted using subject‐space total WM masks. Total WM masks were created using the <italic toggle="yes">Atropos</italic>
<xref rid="acn351421-bib-0016" ref-type="bibr"><sup>16</sup></xref> tool in ANTs<xref rid="acn351421-bib-0017" ref-type="bibr"><sup>17</sup></xref> to segment FA images into WM fraction maps, which were thresholded at 0.7 and binarized. For each time point for each participant, DTI parameter maps were masked using total WM masks and <italic toggle="yes">fslstats</italic>
<xref rid="acn351421-bib-0018" ref-type="bibr"><sup>18</sup></xref> was used to extract mean DTI measures in total WM. For additional region of interest (ROI) analyses, template‐space WM ROIs from the JHU DTI atlas<xref rid="acn351421-bib-0019" ref-type="bibr"><sup>19</sup></xref> were warped into subject‐space, and mean DTI measures from each ROI for each time point were extracted.</p>
                <p>T1‐weighted images were bias field‐corrected and segmented into GM, WM, and cerebrospinal fluid (CSF) using an adaptive maximum <italic toggle="yes">a posteriori</italic> (AMAP) approach<xref rid="acn351421-bib-0020" ref-type="bibr"><sup>20</sup></xref> in the Computational Anatomy Toolbox (CAT12, <ext-link xlink:href="http://www.neuro.uni-jena.de/cat/" ext-link-type="uri">http://www.neuro.uni‐jena.de/cat/</ext-link>) in SPM12 (<ext-link xlink:href="https://www.fil.ion.ucl.ac.uk/spm/" ext-link-type="uri">https://www.fil.ion.ucl.ac.uk/spm/</ext-link>). Prior to further processing, all segmentation maps were visually inspected; furthermore, quantitative CAT12 quality ratings (scored out of 100) did not differ between treatment groups (84.7 ± 1.3 for placebo vs 84.5 ± 1.8 for simvastatin; <italic toggle="yes">t</italic>‐test, <italic toggle="yes">t</italic> = 1.22, <italic toggle="yes">P</italic> = 0.22). Total relative volumes of GM and WM were calculated by dividing total GM and WM volumes by total intracranial volume (TIV; the total sum of GM, WM, and CSF volumes).</p>
                <p>White matter hyperintensities (WMHs) were segmented using T1‐weighted and FLAIR images and the lesion growth algorithm<xref rid="acn351421-bib-0021" ref-type="bibr"><sup>21</sup></xref> (default kappa threshold of 0.3) as implemented in the LST toolbox version 2.0.15 (<ext-link xlink:href="http://www.statisticalmodelling.de/lst.html" ext-link-type="uri">www.statisticalmodelling.de/lst.html</ext-link>) for SPM12. Lesion maps were all visually inspected prior to further analysis.</p>
              </sec>
              <sec id="acn351421-sec-0011">
                <title>Tract‐based spatial statistics (TBSS) processing</title>
                <p>We performed voxel‐wise tract‐based spatial statistics (TBSS)<xref rid="acn351421-bib-0022" ref-type="bibr"><sup>22</sup></xref> in order to assess both baseline differences in WM microstructure between treatment groups, as well as the regional effects of simvastatin on longitudinal WM microstructure. To avoid bias from treatment or temporal effects when normalizing subject images to a common voxel space, we first used iterative groupwise non‐linear registration in ANTs to generate a within‐subject longitudinal average FA image for each subject using FA maps from all four time points. These within‐subject average FA images were then used as inputs to construct an unbiased population‐space template, which was subsequently non‐linearly registered to FSL’s “FMRIB58_FA” standard‐space image.<xref rid="acn351421-bib-0023" ref-type="bibr"><sup>23</sup></xref> Subject‐space DTI parameter maps were then aligned to standard‐space using the warp fields generated during the previous normalization steps (e.g., generating within‐subject average images, constructing the population‐space template, and registering to standard‐space). Standard‐space FA images were merged and averaged to create a mean FA image, which was skeletonized and thresholded at 0.3. Finally, each subject’s aligned FA, MD, AD, and RD parameter maps for all time points were projected onto this skeleton and used as inputs in voxel‐wise statistical analyses.</p>
              </sec>
              <sec id="acn351421-sec-0012">
                <title>Statistical analysis</title>
                <p>All statistical analyses (except voxel‐wise analyses) were performed using R, version 3.6.1 (R Foundation for Statistical Computing). In order to assess the effect of simvastatin on longitudinal WM microstructure, mean DTI measures in global WM were expressed as percent change from baseline at 6, 12, and 18 months, and ANCOVA models were used to assess differences between simvastatin and placebo groups at each time point. Identical models tested treatment × sex and treatment × <italic toggle="yes">APOE</italic>‐ɛ4 genotype interactions. ANCOVA models were used to evaluate percent change in total relative GM, WM, and WMH lesion volume (all corrected for TIV) at each time point. All models included age, sex, and <italic toggle="yes">APOE</italic>‐ɛ4 genotype as covariates.</p>
                <p>Voxel‐wise TBSS analyses were performed using skeletonized standard‐space DTI parameter maps in FSL’s <italic toggle="yes">randomise</italic>
<xref rid="acn351421-bib-0024" ref-type="bibr"><sup>24</sup></xref> (10,000 permutations) followed by threshold‐free cluster enhancement.<xref rid="acn351421-bib-0025" ref-type="bibr"><sup>25</sup></xref> Baseline differences between treatment groups were assessed using baseline DTI maps, while longitudinal analyses used maps representing percent change in DTI measures at 18 months (calculated as [18m image – baseline image]/baseline image × 100). Separate contrasts tested both simvastatin group &gt; placebo group and simvastatin group &lt; placebo group for baseline and longitudinal analyses for all DTI metrics, and all analyses included age, sex, and <italic toggle="yes">APOE</italic>‐ɛ4 genotype as covariates. Resulting statistical maps were family‐wise error (FWE)‐corrected at <italic toggle="yes">P</italic>
<sub>FWE</sub> &lt; 0.05. To provide quantification of longitudinal TBSS results, significant voxels from the statistical maps were deprojected from the skeleton and warped back into each subject’s native imaging space. Mean values across all significant voxels were then extracted from the respective DTI parameter maps for each subject.</p>
                <p>Follow up exploratory voxel‐based morphometry (VBM) analyses were performed to investigate regional effects of simvastatin on WM volume. Template‐space WM segmentation maps (generated by default during CAT12 processing) representing percent change in WM at 12 and 18 months were used in <italic toggle="yes">randomise</italic> (10,000 permutations with threshold‐free cluster enhancement), and models included age, sex, and <italic toggle="yes">APOE</italic>‐ɛ4 genotype as covariates.</p>
                <p>Finally, we tested whether the effects of simvastatin on WM microstructure were mediated by change in serum cholesterol levels with the application of the counterfactual framework mediation analysis method<xref rid="acn351421-bib-0026" ref-type="bibr"><sup>26</sup></xref> using the mediation package (version 4.5.0) in R. Confidence intervals for the indirect (mediation), direct, and total effects were constructed using nonparametric bootstrapping with 10,000 bootstrapped samples. In these analyses, the mediator variable was percent change in serum total cholesterol at 18 months, and the outcome variable was mean percent change in DTI metrics at 18 months within the deprojected significant voxels (from the respective TBSS analyses for each DTI metric). A treatment×mediator interaction term was included in all models. Age, sex, and <italic toggle="yes">APOE</italic>‐ɛ4 genotype were included as covariates.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="acn351421-sec-0013">
              <title>Results</title>
              <sec id="acn351421-sec-0014">
                <title>Participant characteristics and changes in serum cholesterol levels</title>
                <p>Simvastatin and placebo groups did not differ with respect to demographic, laboratory, or neuroimaging measures at study baseline (Table <xref rid="acn351421-tbl-0002" ref-type="table">2</xref>). At all follow‐up time points, the simvastatin‐treated participants had significantly lower serum LDL cholesterol and total cholesterol relative to the placebo‐treated participants (Table <xref rid="acn351421-tbl-0003" ref-type="table">3</xref>). By 18 months, LDL cholesterol had decreased by 42.5% (53 ± 23 mg/dL) in the simvastatin group compared to 5.5% (8 ± 23 mg/dL) in the placebo group, and total cholesterol had decreased by 25.1% (53 ± 25 mg/dL) in the simvastatin group compared to 3.3% (9 ± 31 mg/dL) in the placebo group.</p>
                <table-wrap position="float" id="acn351421-tbl-0002" content-type="Table">
                  <label>Table 2</label>
                  <caption>
                    <p>Participant demographic, laboratory characteristics, and neuroimaging measures at study baseline.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p>Placebo</p>
                          <p>(<italic toggle="yes">n</italic> = 38)</p>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p>Simvastatin</p>
                          <p>(<italic toggle="yes">n</italic> = 35)</p>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, mean (SD), y</td>
                        <td align="left" rowspan="1" colspan="1">55.7 (8.0)</td>
                        <td align="left" rowspan="1" colspan="1">56.7 (6.3)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.57</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Female sex, No. (%)</td>
                        <td align="left" rowspan="1" colspan="1">29 (76.3)</td>
                        <td align="left" rowspan="1" colspan="1">24 (68.6)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.63</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">White/Caucasian race, No. (%)</td>
                        <td align="left" rowspan="1" colspan="1">37 (97.4)<xref rid="acn351421-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="left" rowspan="1" colspan="1">35 (100)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&gt;0.99</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"><italic toggle="yes">APOE</italic>‐ɛ4 positive, No. (%)</td>
                        <td align="left" rowspan="1" colspan="1">14 (36.8)</td>
                        <td align="left" rowspan="1" colspan="1">14 (40.0)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.97</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ASCVD 10‐y risk score, median [IQR]</td>
                        <td align="left" rowspan="1" colspan="1">2.3 [1.2‐4.8]</td>
                        <td align="left" rowspan="1" colspan="1">2.8 [1.6‐6.7]</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.38</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BMI, mean (SD)</td>
                        <td align="left" rowspan="1" colspan="1">28.0 (5.8)</td>
                        <td align="left" rowspan="1" colspan="1">28.0 (6.0)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.98</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Blood pressure</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic, mean (SD), mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">124 (18)</td>
                        <td align="left" rowspan="1" colspan="1">125 (17)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.89</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diastolic, mean (SD), mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">73 (11)</td>
                        <td align="left" rowspan="1" colspan="1">73 (11)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.73</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Antihypertensive medication use, No. (%)</td>
                        <td align="left" rowspan="1" colspan="1">7 (18.4)</td>
                        <td align="left" rowspan="1" colspan="1">6 (17.1)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&gt;0.99</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Current smoker, No. (%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2.6)</td>
                        <td align="left" rowspan="1" colspan="1">3 (8.6)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.55</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Alcohol use in last month, No. (%)</td>
                        <td align="left" rowspan="1" colspan="1">30 (78.9)</td>
                        <td align="left" rowspan="1" colspan="1">30 (85.7)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.65</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Serum lipid profile (fasting)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total cholesterol, mean (SD), mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">209 (35)</td>
                        <td align="left" rowspan="1" colspan="1">205 (37)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.56</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Triglycerides, mean (SD), mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">103 (41)</td>
                        <td align="left" rowspan="1" colspan="1">112 (58)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.45</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">HDL‐C, mean (SD), mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">64 (17)</td>
                        <td align="left" rowspan="1" colspan="1">62 (21)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.75</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL‐C, mean (SD), mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">125 (29)</td>
                        <td align="left" rowspan="1" colspan="1">120 (30)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.45</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Neuroimaging measures</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">DTI metrics (global white matter)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fractional anisotropy (FA), mean (SD)</td>
                        <td align="left" rowspan="1" colspan="1">0.424 (0.014)</td>
                        <td align="left" rowspan="1" colspan="1">0.428 (0.013)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.15</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean diffusivity (MD), mean (SD), 10<sup>−3</sup> mm<sup>3</sup>/s</td>
                        <td align="left" rowspan="1" colspan="1">0.785 (0.024)</td>
                        <td align="left" rowspan="1" colspan="1">0.784 (0.027)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.83</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Radial diffusivity (RD), mean (SD), 10<sup>−3</sup> mm<sup>3</sup>/s</td>
                        <td align="left" rowspan="1" colspan="1">0.591 (0.024)</td>
                        <td align="left" rowspan="1" colspan="1">0.587 (0027)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.54</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Axial diffusivity (AD), mean (SD), 10<sup>−3</sup> mm<sup>3</sup>/s</td>
                        <td align="left" rowspan="1" colspan="1">1.175 (0.028)</td>
                        <td align="left" rowspan="1" colspan="1">1.178 (0.030)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.61</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total GM volume, mean (SD), mL</td>
                        <td align="left" rowspan="1" colspan="1">627 (56)</td>
                        <td align="left" rowspan="1" colspan="1">633 (58)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.67</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total WM volume, mean (SD), mL</td>
                        <td align="left" rowspan="1" colspan="1">508 (60)</td>
                        <td align="left" rowspan="1" colspan="1">508 (61)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.98</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total intracranial volume (TIV), mean (SD), mL</td>
                        <td align="left" rowspan="1" colspan="1">1436 (134)</td>
                        <td align="left" rowspan="1" colspan="1">1446 (130)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.75</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total WMH lesion volume, median [IQR], mL</td>
                        <td align="left" rowspan="1" colspan="1">0.72 [0.19‐1.47]</td>
                        <td align="left" rowspan="1" colspan="1">0.45 [0.17‐1.69]</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.81</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="acn351421-ntgp-0002">
                    <fn id="acn351421-note-0002">
                      <p>Abbreviations: <italic toggle="yes">APOE</italic>, apolipoprotein E; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; DTI, diffusion tensor imaging; GM, gray matter; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; WM, white matter; WMH, whitematter hyperintensity.</p>
                    </fn>
                    <fn id="acn351421-note-0003">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>One American Indian/Native American participant in placebo group.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <table-wrap position="float" id="acn351421-tbl-0003" content-type="Table">
                  <label>Table 3</label>
                  <caption>
                    <p>Fasting serum lipid profiles for simvastatin and placebo groups at 6, 12, and 18 months.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="bottom" colspan="1">Serum lipid profile (fasting)</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">6 months</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">12 months</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">18 months</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <p>Placebo</p>
                          <p>(<italic toggle="yes">n</italic> = 38)</p>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <p>Simvastatin</p>
                          <p>(<italic toggle="yes">n</italic> = 35)</p>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">P</italic> Value</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <p>Placebo</p>
                          <p>(<italic toggle="yes">n</italic> = 38)</p>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <p>Simvastatin</p>
                          <p>(<italic toggle="yes">n</italic> = 35)</p>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">P</italic> Value</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <p>Placebo</p>
                          <p>(n = 38)</p>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <p>Simvastatin</p>
                          <p>(n = 35)</p>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <p>Total cholesterol,</p>
                          <p>mean (SD), mg/dL</p>
                        </td>
                        <td align="char" char="(" rowspan="1" colspan="1">203 (29)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">142 (25)</td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>&lt;0.001</bold>
                        </td>
                        <td align="char" char="(" rowspan="1" colspan="1">204 (32)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">148 (28)</td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>&lt;0.001</bold>
                        </td>
                        <td align="char" char="(" rowspan="1" colspan="1">200 (31)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">152 (26)</td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>&lt;0.001</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <p>Triglycerides,</p>
                          <p>mean (SD), mg/dL</p>
                        </td>
                        <td align="char" char="(" rowspan="1" colspan="1">109 (64)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">88 (45)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.11</td>
                        <td align="char" char="(" rowspan="1" colspan="1">102 (44)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">96 (50)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.60</td>
                        <td align="char" char="(" rowspan="1" colspan="1">113 (83)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">91 (48)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.17</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <p>HDL‐C,</p>
                          <p>mean (SD), mg/dL</p>
                        </td>
                        <td align="char" char="(" rowspan="1" colspan="1">64 (19)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">63 (19)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.79</td>
                        <td align="char" char="(" rowspan="1" colspan="1">65 (19)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">66 (22)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.97</td>
                        <td align="char" char="(" rowspan="1" colspan="1">64 (22)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">66 (20)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.58</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <p>LDL‐C,</p>
                          <p>mean (SD), mg/dL</p>
                        </td>
                        <td align="char" char="(" rowspan="1" colspan="1">117 (26)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">62 (21)</td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>&lt;0.001</bold>
                        </td>
                        <td align="char" char="(" rowspan="1" colspan="1">118 (29)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">64 (19)</td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>&lt;0.001</bold>
                        </td>
                        <td align="char" char="(" rowspan="1" colspan="1">117 (28)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">67 (18)</td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold>&lt;0.001</bold>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="acn351421-ntgp-0003">
                    <fn id="acn351421-note-0004">
                      <p>Abbreviations: HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol. Bold text represents significant <italic toggle="yes">P</italic> value &lt; 0.05.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="acn351421-sec-0015">
                <title>Effect of simvastatin on WM microstructure</title>
                <p>We first tested the effects of simvastatin treatment on global WM microstructure. At 18 months, the percent change in FA and RD in global WM was significantly different between treatment groups (Fig. <xref rid="acn351421-fig-0002" ref-type="fig">2A</xref>; Supplemental Table <xref rid="acn351421-sup-0001" ref-type="supplementary-material">S2</xref>). Specifically, change in FA from baseline at 18 months was −1.25 ± 0.23% in the placebo group compared to −0.40 ± 0.22% in the simvastatin group (adjusted difference in group means 0.88%, 95% CI 0.27 to 1.50, <italic toggle="yes">P</italic> = 0.005). Additionally, change in RD from baseline at 18 months was 0.37 ± 0.36% in the placebo group compared to −0.66 ± 0.36% in the simvastatin group (adjusted difference in group means −1.10%, 95% CI −2.13 to −0.06, <italic toggle="yes">P</italic> = 0.039). There were no significant differences between treatment groups for MD and AD in global WM, and no significant treatment × sex or treatment×<italic toggle="yes">APOE</italic>‐ɛ4 genotype interactions for any DTI metrics.</p>
                <fig position="float" fig-type="Figure" id="acn351421-fig-0002">
                  <label>Figure 2</label>
                  <caption>
                    <p>(A) Longitudinal trajectories of mean diffusion tensor imaging (DTI) metrics within global white matter (WM) for placebo and simvastatin groups over 18 months. At 18 months, the percent change in fractional anisotropy (FA) and radial diffusivity (RD) in global WM was significantly different between treatment groups. *<italic toggle="yes">P</italic> &lt; 0.05. (B) Tract‐based spatial statistics (TBSS) results showing voxels in WM with significantly different percent change in DTI measures at 18 months for FA, mean diffusivity (MD), and RD (10,000 permutations, familywise error‐corrected <italic toggle="yes">P</italic> &lt; 0.05). There were no significant voxels for axial diffusivity (AD). Dot plots to the right of axial slices show the mean percent change (± standard deviation) within significant voxels for placebo and simvastatin groups.</p>
                  </caption>
                  <graphic xlink:href="ACN3-8-1656-g001" position="anchor" id="jats-graphic-3"/>
                </fig>
                <p>We next used voxel‐wise TBSS analyses in order to further assess the effects of simvastatin on regional WM microstructure. There were significant differences between treatment groups for 18‐month percent change in FA, MD, and RD throughout extensive regions of the WM skeleton, with more widespread effects observed for FA and RD than MD (Fig. <xref rid="acn351421-fig-0002" ref-type="fig">2B</xref>). Significant voxel clusters were located in areas corresponding to major WM tracts (corpus callosum, corticospinal tract, anterior thalamic radiation, inferior longitudinal fasciculus, superior longitudinal fasciculus, inferior fronto‐occipital fasciculus) as well as brainstem WM regions (cerebellar peduncle). Within significant clusters, FA change from baseline was −1.9 ± 1.6% in the placebo group compared to 1.4 ± 1.6% in the simvastatin group; MD and RD change from baseline was 1.1 ± 1.5% and 1.8 ± 2.3%, respectively, in the placebo group compared to −1.9 ± 1.4% and −2.6 ± 2.0%, respectively, in the simvastatin group. Notably, there were no significant voxels where FA percent change was lower, or where MD or RD percent change was higher, in the simvastatin group compared to the placebo group after 18 months. Additionally, there were no significant voxels where AD percent change was different between treatment groups. An ROI analyses using predefined WM ROIs from the JHU tractography atlas showed similar results (Supplemental Fig. <xref rid="acn351421-sup-0001" ref-type="supplementary-material">S1</xref>). Out of eleven ROIs, FA was significantly altered in nine regions, MD was significantly altered in four regions, and RD was significantly altered in seven regions. The simvastatin group showed the greatest differences in corpus callosum (forceps major and minor) and inferior fronto‐occipital fasciculus.</p>
              </sec>
              <sec id="acn351421-sec-0016">
                <title>Effect of simvastatin on GM, WM, and WMH volume</title>
                <p>While there were no significant effects of treatment on longitudinal total GM volume, the simvastatin group showed significantly different percent change in total WM volume at 12 and 18 months compared to the placebo group (Fig. <xref rid="acn351421-fig-0003" ref-type="fig">3A</xref>). At 12 months, change in WM volume from baseline was −0.33 ± 0.23% in the placebo group compared to 0.43 ± 0.25% in the simvastatin group (adjusted difference in group means 0.77%, 95% CI 0.10 to 1.43, <italic toggle="yes">P</italic> = 0.026). At 18 months, change in WM volume from baseline was −0.64 ± 0.20% in the placebo group compared to 0.06 ± 0.21% in the simvastatin group (adjusted difference in group means 0.72%, 95% CI 0.13 to 1.32, <italic toggle="yes">P</italic> = 0.018). Exploratory VBM analyses showed that these effects were distributed throughout WM, with strongest effects occurring in bilateral anterior temporal and superior frontal WM regions (Supplemental Fig. <xref rid="acn351421-sup-0001" ref-type="supplementary-material">S2</xref>). There were no significant treatment effects on longitudinal WMH lesion volume (Fig. <xref rid="acn351421-fig-0003" ref-type="fig">3B</xref>).</p>
                <fig position="float" fig-type="Figure" id="acn351421-fig-0003">
                  <label>Figure 3</label>
                  <caption>
                    <p>Longitudinal trajectories of (A) gray matter (GM) volume, white matter (WM) volume, and (B) white matter hyperintensity (WMH) lesion volume for placebo and simvastatin groups over 18 months. The simvastatin group showed significantly different percent change in total WM volume at 12 and 18 months compared to the placebo group. There were no significant differences in GM or WMH volume changes between placebo and simvastatin groups. * <italic toggle="yes">P</italic> &lt; 0.05.</p>
                  </caption>
                  <graphic xlink:href="ACN3-8-1656-g003" position="anchor" id="jats-graphic-5"/>
                </fig>
              </sec>
              <sec id="acn351421-sec-0017">
                <title>Mediation of change in WM microstructure by change in serum total cholesterol</title>
                <p>We found that the effect of simvastatin on change in WM microstructure was partially mediated by the percent change in serum total cholesterol (Fig. <xref rid="acn351421-fig-0004" ref-type="fig">4</xref>). Change in serum total cholesterol mediated 28%, 32%, and 29% of the total effect for FA, MD, and RD, respectively. Visualizing this relationship showed that individuals with the greatest change in total cholesterol levels had the generally had the greatest change in DTI measures (Supplemental Fig. <xref rid="acn351421-sup-0001" ref-type="supplementary-material">S3</xref>).</p>
                <fig position="float" fig-type="Figure" id="acn351421-fig-0004">
                  <label>Figure 4</label>
                  <caption>
                    <p>Models and results for mediation analyses for change in total cholesterol mediating the effect of simvastatin on change in white matter microstructure. (A) Conceptual model of mediation pathway and model parameters. For each model, the mediator variable was percent change in serum total cholesterol at 18 months, and the white matter microstructure outcome was mean percent change in DTI metrics within significant voxels (from the TBSS analyses) at 18 months. For all three DTI metrics (B‐D), the effect of simvastatin on change in white matter microstructure was partially mediated by the percent change in total cholesterol. Beta‐coefficients are shown for the mediation, direct, and total effects, along with bootstrapped 95% confidence intervals (10,000 iterations). <sup>§</sup>
<italic toggle="yes">P</italic> = 0.06; * <italic toggle="yes">P</italic> &lt; 0.05; *** <italic toggle="yes">P</italic> &lt; 0.001.</p>
                  </caption>
                  <graphic xlink:href="ACN3-8-1656-g004" position="anchor" id="jats-graphic-7"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion" id="acn351421-sec-0018">
              <title>Discussion</title>
              <p>In this analysis of longitudinal neuroimaging data acquired during a randomized controlled trial, simvastatin treatment in healthy, statin‐naïve, cognitively unimpaired adults resulted in significantly altered WM microstructure and volume over 18 months compared to placebo treatment. Specifically, while the placebo group showed longitudinal changes consistent with gradual age‐related reductions in WM microstructure (decreased FA and AD, increased RD),<xref rid="acn351421-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="acn351421-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="acn351421-bib-0029" ref-type="bibr"><sup>29</sup></xref> the simvastatin group showed distinctly altered trajectories, such that by 18 months, decline in FA was significantly attenuated and RD was decreased relative to baseline. Additionally, longitudinal TBSS analyses demonstrated that these effects were widely distributed throughout cerebral and brainstem WM. Notably, within significant voxels, placebo, and simvastatin groups showed WM microstructural changes in opposing directions, suggesting an effect of simvastatin that is opposite to apparent age‐related changes. Finally, while the placebo group showed gradual decline in WM volume, the simvastatin group showed virtually no change from baseline in WM volume at 18 months. Taken together, these results suggest that simvastatin treatment resulted in preserved WM microstructure and volume over 18 months compared to placebo treatment.</p>
              <p>Given its sensitivity to restricted diffusion of water molecules, DTI provides insight in WM architecture. Within WM, RD (the magnitude of diffusivity perpendicular to the principle direction of hindered diffusion) and AD (the magnitude of diffusivity along the principle direction of hindered diffusion) are commonly regarded as surrogate measures of myelin and axonal integrity, respectively.<xref rid="acn351421-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="acn351421-bib-0031" ref-type="bibr"><sup>31</sup></xref>, <xref rid="acn351421-bib-0032" ref-type="bibr"><sup>32</sup></xref>, <xref rid="acn351421-bib-0033" ref-type="bibr"><sup>33</sup></xref> In the current study, simvastatin treatment resulted in significant changes in RD, but not AD, suggesting an effect on myelin, but not axonal integrity. Interestingly, the simvastatin group showed decreased RD from baseline at 18 months, potentially indicating increased myelin content as a result of statin treatment. However, DTI metrics are indirect measures of tissue microstructure, and histopathological correlation is required to confirm these changes.</p>
              <p>Results from prior observational studies of the effects of statins on WM microstructure have been mixed. In a study of community‐dwelling elderly adults, statin‐exposure was associated with higher FA in global WM, but only in individuals in the lowest tertile of cognitive performance.<xref rid="acn351421-bib-0009" ref-type="bibr"><sup>9</sup></xref> Alternatively, in a large population‐based study of &gt;1100 older adults, long‐term (&gt;5 yrs) statin exposure was associated with lower FA in the genu of the corpus callosum, although this finding was driven by increased cardiovascular disease risk factors in statin‐exposed individuals.<xref rid="acn351421-bib-0010" ref-type="bibr"><sup>10</sup></xref> It is important to note that statin type, dose, and duration of use differed within the statin‐exposed individuals in both of these studies, and it is unknown whether WM microstructure alterations existed prior to initiation of statin treatment. In the current study, the use of data collected during a randomized control trial in statin‐naïve adults provides strong evidence that simvastatin impacts WM microstructure over time, even in cognitively unimpaired individuals with low cardiovascular disease risk.</p>
              <p>Statins may affect WM through both peripheral and central pathways.<xref rid="acn351421-bib-0034" ref-type="bibr"><sup>34</sup></xref> One potential peripheral pathway is through lowering circulating cholesterol levels, and previous studies have shown that both higher LDL cholesterol and lower HDL cholesterol levels are associated with lower WM microstructural integrity in cognitively unimpaired older adults.<xref rid="acn351421-bib-0035" ref-type="bibr"><sup>35</sup></xref>, <xref rid="acn351421-bib-0036" ref-type="bibr"><sup>36</sup></xref>, <xref rid="acn351421-bib-0037" ref-type="bibr"><sup>37</sup></xref> In the current study, we tested this peripheral pathway using mediation analysis and found that approximately 30% of the effect of simvastatin on WM microstructure was mediated by changes in serum total cholesterol levels. Although the exact mechanisms by which reducing peripheral cholesterol may affect brain WM are uncertain, lower circulating cholesterol may reduce atherosclerosis and improve cerebrovascular health, even in individuals with generally low vascular disease risk. Additionally, reduction in serum cholesterol may be a surrogate measure for other peripheral effects of statins, including reducing endothelial dysfunction and vascular inflammation.<xref rid="acn351421-bib-0038" ref-type="bibr"><sup>38</sup></xref> In the present study, it is worth noting that simvastatin treatment did not appear to affect WMH lesion volume, a commonly used neuroimaging marker of small vessel cerebrovascular disease.<xref rid="acn351421-bib-0039" ref-type="bibr"><sup>39</sup></xref> However, the pathophysiology of WMH burden is multifactorial and may be more attributed to hypertension,<xref rid="acn351421-bib-0040" ref-type="bibr"><sup>40</sup></xref>, <xref rid="acn351421-bib-0041" ref-type="bibr"><sup>41</sup></xref> which was unaffected by simvastatin. Additionally, peripheral mechanisms including improved endothelial dysfunction and reduced vascular inflammation would likely not be detected with WMH lesion volume, and future studies directly measuring peripheral vascular markers and WM health are needed.</p>
              <p>While mediation analyses suggest that lowering peripheral cholesterol levels contributed to a portion of the effect of simvastatin on preserving WM integrity, they also indicate that a majority of the effect of simvastatin on WM microstructure occurred through other pathways, including central pathways. Simvastatin is a lipophilic statin capable of crossing the BBB and may affect WM by directly affecting cholesterol homeostasis in the brain. Previous clinical studies have shown that statin treatment not only generally reduces brain cholesterol synthesis, but also decreases brain cholesterol efflux,<xref rid="acn351421-bib-0042" ref-type="bibr"><sup>42</sup></xref>, <xref rid="acn351421-bib-0043" ref-type="bibr"><sup>43</sup></xref>, <xref rid="acn351421-bib-0044" ref-type="bibr"><sup>44</sup></xref>, <xref rid="acn351421-bib-0045" ref-type="bibr"><sup>45</sup></xref> suggesting compensatory mechanisms to maintain cholesterol levels in the brain. Notably, a study evaluating the effects of long‐term statin treatment (&gt;12 months) observed initial reduction in brain cholesterol synthesis and metabolites, followed by a return to baseline and overshoot at 2 years.<xref rid="acn351421-bib-0045" ref-type="bibr"><sup>45</sup></xref> Intriguingly, this pattern of compensatory cholesterol metabolism resembles the trajectories of DTI metrics observed for the simvastatin group in the current study. This was particularly the case for RD, which showed an initial increase at 6 months followed by eventual decrease at 18 months. Finally, in addition to directly affecting brain cholesterol homeostasis, statins also have pleotropic effects in the brain.<xref rid="acn351421-bib-0007" ref-type="bibr"><sup>7</sup></xref> By inhibiting production of brain isoprenoids (a downstream intermediate in the cholesterol synthesis pathway), statins can reduce neuroinflammation and oxidative stress,<xref rid="acn351421-bib-0046" ref-type="bibr"><sup>46</sup></xref>, <xref rid="acn351421-bib-0047" ref-type="bibr"><sup>47</sup></xref> which may have beneficial effects on WM integrity. Overall, simvastatin treatment likely leads to preservation of WM through both peripheral and central effects, in which improvement in cerebrovascular health may be augmented by upregulating brain cholesterol recycling or reducing neuroinflammation.</p>
              <p>While a major strength of the current study is the use of longitudinal data collected during a randomized controlled trial, the treatment groups were relatively small and were racially homogenous. Additionally, all participants had a parental family history of Alzheimer’s disease dementia. Thus, it remains to be determined whether the effects of simvastatin on WM generalize to larger samples that are more representative of the general population. However, in the current study, there was no evidence of interaction between treatment and <italic toggle="yes">APOE</italic>‐ɛ4 genotype, suggesting that the effects of simvastatin are independent of Alzheimer’s disease genetic risk. Additionally, this study included a relatively large age range of participants (40–72 years old), and the small sample size did not allow us to determine whether the effects of simvastatin on WM are more pronounced in certain ages. Finally, future studies extending longer than 18 months are needed in order to determine the longevity and persistence of the effects of simvastatin on WM integrity.</p>
            </sec>
            <sec sec-type="conclusions" id="acn351421-sec-0019">
              <title>Conclusions</title>
              <p>Statins are prescribed for millions of adults, yet whether these medications affect cholesterol‐rich WM regions in the brain is largely unknown. Here, we show that simvastatin, a lipophilic statin capable of crossing the BBB, preserves WM microstructure and volume in healthy, cognitively unimpaired middle‐aged adults. While statins have been proposed as therapeutic agents for neurodegenerative conditions, including Alzheimer’s disease, clinical trials have largely been negative,<xref rid="acn351421-bib-0048" ref-type="bibr"><sup>48</sup></xref>, <xref rid="acn351421-bib-0049" ref-type="bibr"><sup>49</sup></xref> potentially due to inadequate duration of therapy or intervention occurring well after development of cognitive impairment. Future studies are needed to replicate these findings and determine whether the effects of simvastatin on WM structure translate into delaying or preventing cognitive changes.</p>
            </sec>
            <sec id="acn351421-sec-0021">
              <title>Author Contributions</title>
              <p>NMV, JFVH, YM, CAV, RJC, KLK, LEJ, BPA, SA, SCJ, BBB, and CMC were involved in conception and design of the study. NMV, JFVH, YM, CAV, NA, RJC, KLK, LEJ, and BPA assisted in acquisition and analysis of data. NMV, JFVH, BBB, and CMC were involved in drafting the manuscript.</p>
            </sec>
            <sec sec-type="COI-statement" id="acn351421-sec-0022">
              <title>Conflicts of Interest</title>
              <p>Nothing to report.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="acn351421-sup-0001" position="float" content-type="local-data">
                <caption>
                  <p><bold>Supplemental File S1.</bold> Supplemental material including tables and figures.</p>
                </caption>
                <media xlink:href="ACN3-8-1656-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="acn351421-sec-0020">
              <title>Acknowledgments</title>
              <p>We thank the staff and researchers at the University of Wisconsin Alzheimer’s Disease Research Center for their assistance in study organization, participant recruitment, and facilitating data availability. We extend our thanks to the committed research participants at the UW ADRC who make this work possible.</p>
            </ack>
            <ref-list content-type="cited-references" id="acn351421-bibl-0001">
              <title>References</title>
              <ref id="acn351421-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0001"><string-name><surname>Dietschy</surname><given-names>JM</given-names></string-name>, <string-name><surname>Turley</surname><given-names>SD</given-names></string-name>. <article-title>Cholesterol metabolism in the central nervous system during early development and in the mature animal</article-title>. <source>J Lipid Res</source><year>2004</year>;<volume>45</volume>(<issue>8</issue>):<fpage>1375</fpage>–<lpage>1397</lpage>.<pub-id pub-id-type="pmid">15254070</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0002"><string-name><surname>Björkhem</surname><given-names>I</given-names></string-name>, <string-name><surname>Meaney</surname><given-names>S</given-names></string-name>. <article-title>Brain cholesterol: long secret life behind a barrier</article-title>. <source>Arteriosclerosis Thrombosis Vasc Biology</source><year>2004</year>;<volume>24</volume>(<issue>5</issue>):<fpage>806</fpage>–<lpage>815</lpage>.</mixed-citation>
              </ref>
              <ref id="acn351421-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0003"><string-name><surname>Saher</surname><given-names>G</given-names></string-name>, <string-name><surname>Brügger</surname><given-names>B</given-names></string-name>, <string-name><surname>Lappe‐Siefke</surname><given-names>C</given-names></string-name>, et al. <article-title>High cholesterol level is essential for myelin membrane growth</article-title>. <source>Nat Neurosci</source>
<year>2005</year>;<volume>8</volume>(<issue>4</issue>):<fpage>468</fpage>–<lpage>475</lpage>.<pub-id pub-id-type="pmid">15793579</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0004"><string-name><surname>Nieweg</surname><given-names>K</given-names></string-name>, <string-name><surname>Schaller</surname><given-names>H</given-names></string-name>, <string-name><surname>Pfrieger</surname><given-names>FW</given-names></string-name>. <article-title>Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats</article-title>. <source>J Neurochem</source><year>2009</year>;<volume>109</volume>(<issue>1</issue>):<fpage>125</fpage>–<lpage>134</lpage>.<pub-id pub-id-type="pmid">19166509</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0005"><string-name><surname>Björkhem</surname><given-names>I</given-names></string-name>, <string-name><surname>Lütjohann</surname><given-names>D</given-names></string-name>, <string-name><surname>Diczfalusy</surname><given-names>U</given-names></string-name>, et al. <article-title>Cholesterol homeostasis in human brain: turnover of 24S‐hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation</article-title>. <source>J Lipid Res</source>
<year>1998</year>;<volume>39</volume>(<issue>8</issue>):<fpage>1594</fpage>–<lpage>1600</lpage>.<pub-id pub-id-type="pmid">9717719</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0006"><string-name><surname>Sirtori</surname><given-names>CR</given-names></string-name>. <article-title>The pharmacology of statins</article-title>. <source>Pharmacol Res</source><year>2014</year>;<volume>88</volume>:<fpage>3</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">24657242</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0007"><string-name><surname>Fracassi</surname><given-names>A</given-names></string-name>, <string-name><surname>Marangoni</surname><given-names>M</given-names></string-name>, <string-name><surname>Rosso</surname><given-names>P</given-names></string-name>, et al. <article-title>Statins and the brain: more than lipid lowering agents?</article-title>
<source>Curr Neuropharmacol</source>
<year>2018</year>;<volume>17</volume>(<issue>1</issue>):<fpage>59</fpage>–<lpage>83</lpage>.</mixed-citation>
              </ref>
              <ref id="acn351421-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0008"><string-name><surname>Alger</surname><given-names>JR</given-names></string-name>. <article-title>The diffusion tensor imaging toolbox</article-title>. <source>J Neurosci</source><year>2012</year>;<volume>32</volume>(<issue>22</issue>):<fpage>7418</fpage>–<lpage>7428</lpage>.<pub-id pub-id-type="pmid">22649222</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0009"><string-name><surname>Nadkarni</surname><given-names>NK</given-names></string-name>, <string-name><surname>Perera</surname><given-names>S</given-names></string-name>, <string-name><surname>Hanlon</surname><given-names>JT</given-names></string-name>, et al. <article-title>Statins and brain integrity in older adults: secondary analysis of the health ABC study</article-title>. <source>Alzheimer’s Dementia</source>
<year>2015</year>;<volume>11</volume>(<issue>10</issue>):<fpage>1202</fpage>–<lpage>1211</lpage>.</mixed-citation>
              </ref>
              <ref id="acn351421-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0010"><string-name><surname>Ramanan</surname><given-names>VK</given-names></string-name>, <string-name><surname>Przybelski</surname><given-names>SA</given-names></string-name>, <string-name><surname>Graff‐Radford</surname><given-names>J</given-names></string-name>, et al. <article-title>Statins and brain health: Alzheimer’s disease and cerebrovascular disease biomarkers in older adults</article-title>. <source>J Alzheimer’s Dis</source>
<year>2018</year>;Preprint(Preprint):1–8.</mixed-citation>
              </ref>
              <ref id="acn351421-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0011"><string-name><surname>Gepner</surname><given-names>AD</given-names></string-name>, <string-name><surname>Lazar</surname><given-names>K</given-names></string-name>, <string-name><surname>Hulle</surname><given-names>CV</given-names></string-name>, et al. <article-title>Effects of simvastatin on augmentation index are transient: outcomes from a randomized controlled trial</article-title>. <source>J Am Heart Assoc</source>
<year>2019</year>;<volume>8</volume>(<issue>20</issue>):<elocation-id>e009792</elocation-id>.<pub-id pub-id-type="pmid">31607205</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0012"><string-name><surname>Veraart</surname><given-names>J</given-names></string-name>, <string-name><surname>Novikov</surname><given-names>DS</given-names></string-name>, <string-name><surname>Christiaens</surname><given-names>D</given-names></string-name>, et al. <article-title>Denoising of diffusion MRI using random matrix theory</article-title>. <source>NeuroImage</source>
<year>2016</year>;<volume>142</volume>:<fpage>394</fpage>–<lpage>406</lpage>.<pub-id pub-id-type="pmid">27523449</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0013"><string-name><surname>Kellner</surname><given-names>E</given-names></string-name>, <string-name><surname>Dhital</surname><given-names>B</given-names></string-name>, <string-name><surname>Kiselev</surname><given-names>VG</given-names></string-name>, <string-name><surname>Reisert</surname><given-names>M</given-names></string-name>. <article-title>Gibbs‐ringing artifact removal based on local subvoxel‐shifts</article-title>. <source>Magnet Reson Med</source><year>2016</year>;<volume>76</volume>(<issue>5</issue>):<fpage>1574</fpage>–<lpage>1581</lpage>.</mixed-citation>
              </ref>
              <ref id="acn351421-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0014"><string-name><surname>Andersson</surname><given-names>JLR</given-names></string-name>, <string-name><surname>Sotiropoulos</surname><given-names>SN</given-names></string-name>. <article-title>An integrated approach to correction for off‐resonance effects and subject movement in diffusion MR imaging</article-title>. <source>NeuroImage</source><year>2016</year>;<volume>125</volume>:<fpage>1063</fpage>–<lpage>1078</lpage>.<pub-id pub-id-type="pmid">26481672</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0015"><string-name><surname>Garyfallidis</surname><given-names>E</given-names></string-name>, <string-name><surname>Brett</surname><given-names>M</given-names></string-name>, <string-name><surname>Amirbekian</surname><given-names>B</given-names></string-name>, et al. <article-title>Dipy, a library for the analysis of diffusion MRI data</article-title>. <source>Front Neuroinform</source>
<year>2014</year>;<volume>8</volume>:<fpage>8</fpage>.<pub-id pub-id-type="pmid">24600385</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0016"><string-name><surname>Avants</surname><given-names>BB</given-names></string-name>, <string-name><surname>Tustison</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J</given-names></string-name>, et al. <article-title>An open source multivariate framework for n‐tissue segmentation with evaluation on public data</article-title>. <source>Neuroinformatics</source>
<year>2011</year>;<volume>9</volume>(<issue>4</issue>):<fpage>381</fpage>–<lpage>400</lpage>.<pub-id pub-id-type="pmid">21373993</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0017"><string-name><surname>Avants</surname><given-names>BB</given-names></string-name>, <string-name><surname>Tustison</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Song</surname><given-names>G</given-names></string-name>, et al. <article-title>A reproducible evaluation of ANTs similarity metric performance in brain image registration</article-title>. <source>NeuroImage</source>
<year>2011</year>;<volume>54</volume>(<issue>3</issue>):<fpage>2033</fpage>–<lpage>2044</lpage>.<pub-id pub-id-type="pmid">20851191</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0018"><string-name><surname>Jenkinson</surname><given-names>M</given-names></string-name>, <string-name><surname>Beckmann</surname><given-names>CF</given-names></string-name>, <string-name><surname>Behrens</surname><given-names>TEJ</given-names></string-name>, et al. <article-title>Fsl</article-title>. <source>NeuroImage</source>
<year>2012</year>;<volume>62</volume>(<issue>2</issue>):<fpage>782</fpage>–<lpage>790</lpage>.<pub-id pub-id-type="pmid">21979382</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0019"><string-name><surname>Hua</surname><given-names>K</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Wakana</surname><given-names>S</given-names></string-name>, et al. <article-title>Tract probability maps in stereotaxic spaces: analyses of white matter anatomy and tract‐specific quantification</article-title>. <source>NeuroImage</source>
<year>2008</year>;<volume>39</volume>(<issue>1</issue>):<fpage>336</fpage>–<lpage>347</lpage>.<pub-id pub-id-type="pmid">17931890</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0020"><string-name><surname>Rajapakse</surname><given-names>JC</given-names></string-name>, <string-name><surname>Giedd</surname><given-names>JN</given-names></string-name>, <string-name><surname>Rapoport</surname><given-names>JL</given-names></string-name>. <article-title>Statistical approach to segmentation of single‐channel cerebral MR images</article-title>. <source>IEEE T Med Imaging</source><year>1997</year>;<volume>16</volume>(<issue>2</issue>):<fpage>176</fpage>–<lpage>186</lpage>.</mixed-citation>
              </ref>
              <ref id="acn351421-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0021"><string-name><surname>Schmidt</surname><given-names>P</given-names></string-name>, <string-name><surname>Gaser</surname><given-names>C</given-names></string-name>, <string-name><surname>Arsic</surname><given-names>M</given-names></string-name>, et al. <article-title>An automated tool for detection of FLAIR‐hyperintense white‐matter lesions in multiple sclerosis</article-title>. <source>NeuroImage</source>
<year>2012</year>;<volume>59</volume>(<issue>4</issue>):<fpage>3774</fpage>–<lpage>3783</lpage>.<pub-id pub-id-type="pmid">22119648</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0022"><string-name><surname>Smith</surname><given-names>SM</given-names></string-name>, <string-name><surname>Jenkinson</surname><given-names>M</given-names></string-name>, <string-name><surname>Johansen‐Berg</surname><given-names>H</given-names></string-name>, et al. <article-title>Tract‐based spatial statistics: voxelwise analysis of multi‐subject diffusion data</article-title>. <source>NeuroImage</source>
<year>2006</year>;<volume>31</volume>(<issue>4</issue>):<fpage>1487</fpage>–<lpage>1505</lpage>.<pub-id pub-id-type="pmid">16624579</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0023"><string-name><surname>Schwarz</surname><given-names>CG</given-names></string-name>, <string-name><surname>Reid</surname><given-names>RI</given-names></string-name>, <string-name><surname>Gunter</surname><given-names>JL</given-names></string-name>, et al. <article-title>Improved DTI registration allows voxel‐based analysis that outperforms Tract‐Based Spatial Statistics</article-title>. <source>NeuroImage</source>
<year>2014</year>;<volume>94</volume>:<fpage>65</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">24650605</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0024"><string-name><surname>Winkler</surname><given-names>AM</given-names></string-name>, <string-name><surname>Ridgway</surname><given-names>GR</given-names></string-name>, <string-name><surname>Webster</surname><given-names>MA</given-names></string-name>, et al. <article-title>Permutation inference for the general linear model</article-title>. <source>NeuroImage</source>
<year>2014</year>;<volume>92</volume>:<fpage>381</fpage>–<lpage>397</lpage>.<pub-id pub-id-type="pmid">24530839</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0025"><string-name><surname>Smith</surname><given-names>SM</given-names></string-name>, <string-name><surname>Nichols</surname><given-names>TE</given-names></string-name>. <article-title>Threshold‐free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference</article-title>. <source>NeuroImage</source><year>2009</year>;<volume>44</volume>(<issue>1</issue>):<fpage>83</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">18501637</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0026"><string-name><surname>Imai</surname><given-names>K</given-names></string-name>, <string-name><surname>Keele</surname><given-names>L</given-names></string-name>, <string-name><surname>Yamamoto</surname><given-names>T</given-names></string-name>. <article-title>Identification, inference and sensitivity analysis for causal mediation effects</article-title>. <source>Stat Sci</source><year>2010</year>;<volume>25</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>71</lpage>.</mixed-citation>
              </ref>
              <ref id="acn351421-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0027"><string-name><surname>Bennett</surname><given-names>IJ</given-names></string-name>, <string-name><surname>Madden</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Vaidya</surname><given-names>CJ</given-names></string-name>, et al. <article-title>Age‐related differences in multiple measures of white matter integrity: a diffusion tensor imaging study of healthy aging</article-title>. <source>Hum Brain Mapp</source>
<year>2009</year>;<volume>31</volume>(<issue>3</issue>):NA‐NA..</mixed-citation>
              </ref>
              <ref id="acn351421-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0028"><string-name><surname>Burzynska</surname><given-names>AZ</given-names></string-name>, <string-name><surname>Preuschhof</surname><given-names>C</given-names></string-name>, <string-name><surname>Bäckman</surname><given-names>L</given-names></string-name>, et al. <article-title>Age‐related differences in white matter microstructure: region‐specific patterns of diffusivity</article-title>. <source>NeuroImage</source>
<year>2010</year>;<volume>49</volume>(<issue>3</issue>):<fpage>2104</fpage>–<lpage>2112</lpage>.<pub-id pub-id-type="pmid">19782758</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0029"><string-name><surname>Sexton</surname><given-names>CE</given-names></string-name>, <string-name><surname>Walhovd</surname><given-names>KB</given-names></string-name>, <string-name><surname>Storsve</surname><given-names>AB</given-names></string-name>, et al. <article-title>Accelerated changes in white matter microstructure during aging: a longitudinal diffusion tensor imaging study</article-title>. <source>J Neurosci</source>
<year>2014</year>;<volume>34</volume>(<issue>46</issue>):<fpage>15425</fpage>–<lpage>15436</lpage>.<pub-id pub-id-type="pmid">25392509</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0030"><string-name><surname>Song</surname><given-names>S‐K</given-names></string-name>, <string-name><surname>Sun</surname><given-names>S‐W</given-names></string-name>, <string-name><surname>Ramsbottom</surname><given-names>MJ</given-names></string-name>, et al. <article-title>Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water</article-title>. <source>NeuroImage</source>
<year>2002</year>;<volume>17</volume>(<issue>3</issue>):<fpage>1429</fpage>–<lpage>1436</lpage>.<pub-id pub-id-type="pmid">12414282</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0031"><string-name><surname>Song</surname><given-names>S‐K</given-names></string-name>, <string-name><surname>Sun</surname><given-names>S‐W</given-names></string-name>, <string-name><surname>Ju</surname><given-names>W‐K</given-names></string-name>, et al. <article-title>Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia</article-title>. <source>NeuroImage</source>
<year>2003</year>;<volume>20</volume>(<issue>3</issue>):<fpage>1714</fpage>–<lpage>1722</lpage>.<pub-id pub-id-type="pmid">14642481</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0032"><string-name><surname>Song</surname><given-names>S‐K</given-names></string-name>, <string-name><surname>Yoshino</surname><given-names>J</given-names></string-name>, <string-name><surname>Le</surname><given-names>TQ</given-names></string-name>, et al. <article-title>Demyelination increases radial diffusivity in corpus callosum of mouse brain</article-title>. <source>NeuroImage</source>
<year>2005</year>;<volume>26</volume>(<issue>1</issue>):<fpage>132</fpage>–<lpage>140</lpage>.<pub-id pub-id-type="pmid">15862213</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0033"><string-name><surname>Winklewski</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Sabisz</surname><given-names>A</given-names></string-name>, <string-name><surname>Naumczyk</surname><given-names>P</given-names></string-name>, et al. <article-title>Understanding the physiopathology behind axial and radial diffusivity changes—what do we know?</article-title>
<source>Front Neurol</source>
<year>2018</year>;<volume>9</volume>:<fpage>92</fpage>.<pub-id pub-id-type="pmid">29535676</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0034"><string-name><surname>Cibičková</surname><given-names>L</given-names></string-name>. <article-title>Statins and their influence on brain cholesterol</article-title>. <source>J Clin Lipidol</source><year>2011</year>;<volume>5</volume>(<issue>5</issue>):<fpage>373</fpage>–<lpage>379</lpage>.<pub-id pub-id-type="pmid">21981838</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0035"><string-name><surname>Ryu</surname><given-names>C‐W</given-names></string-name>, <string-name><surname>Coutu</surname><given-names>J‐P</given-names></string-name>, <string-name><surname>Greka</surname><given-names>A</given-names></string-name>, et al. <article-title>Differential associations between systemic markers of disease and white matter tissue health in middle‐aged and older adults</article-title>. <source>J Cereb Blood Flow Metabolism</source>
<year>2016</year>;<volume>37</volume>(<issue>11</issue>):<fpage>3568</fpage>–<lpage>3579</lpage>.</mixed-citation>
              </ref>
              <ref id="acn351421-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0036"><string-name><surname>Williams</surname><given-names>VJ</given-names></string-name>, <string-name><surname>Leritz</surname><given-names>EC</given-names></string-name>, <string-name><surname>Shepel</surname><given-names>J</given-names></string-name>, et al. <article-title>Interindividual variation in serum cholesterol is associated with regional white matter tissue integrity in older adults</article-title>. <source>Hum Brain Mapp</source>
<year>2013</year>;<volume>34</volume>(<issue>8</issue>):<fpage>1826</fpage>–<lpage>1841</lpage>.<pub-id pub-id-type="pmid">22438182</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0037"><string-name><surname>Johnson</surname><given-names>NF</given-names></string-name>, <string-name><surname>Gold</surname><given-names>BT</given-names></string-name>, <string-name><surname>Ross</surname><given-names>D</given-names></string-name>, et al. <article-title>Non‐fasting high‐density lipoprotein is associated with white matter microstructure in healthy older adults</article-title>. <source>Front Aging Neurosci</source>
<year>2019</year>;<volume>11</volume>:<fpage>100</fpage>.<pub-id pub-id-type="pmid">31133843</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0038"><string-name><surname>Liao</surname><given-names>JK</given-names></string-name>, <string-name><surname>Laufs</surname><given-names>U</given-names></string-name>. <article-title>Pleiotropic effects of statins</article-title>. <source>Annu Rev Pharmacol</source><year>2005</year>;<volume>45</volume>(<issue>1</issue>):<fpage>89</fpage>–<lpage>118</lpage>.</mixed-citation>
              </ref>
              <ref id="acn351421-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0039"><string-name><surname>Wardlaw</surname><given-names>JM</given-names></string-name>, <string-name><surname>Smith</surname><given-names>C</given-names></string-name>, <string-name><surname>Dichgans</surname><given-names>M</given-names></string-name>. <article-title>Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging</article-title>. <source>Lancet Neurology</source><year>2013</year>;<volume>12</volume>(<issue>5</issue>):<fpage>483</fpage>–<lpage>497</lpage>.<pub-id pub-id-type="pmid">23602162</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0040"><string-name><surname>Gottesman</surname><given-names>RF</given-names></string-name>, <string-name><surname>Coresh</surname><given-names>J</given-names></string-name>, <string-name><surname>Catellier</surname><given-names>DJ</given-names></string-name>, et al. <article-title>Blood pressure and white‐matter disease progression in a biethnic cohort</article-title>. <source>Stroke</source>
<year>2010</year>;<volume>41</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">19926835</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0041"><string-name><surname>Godin</surname><given-names>O</given-names></string-name>, <string-name><surname>Tzourio</surname><given-names>C</given-names></string-name>, <string-name><surname>Maillard</surname><given-names>P</given-names></string-name>, et al. <article-title>Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes</article-title>. <source>Circulation</source>
<year>2011</year>;<volume>123</volume>(<issue>3</issue>):<fpage>266</fpage>–<lpage>273</lpage>.<pub-id pub-id-type="pmid">21220733</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0042"><string-name><surname>Fassbender</surname><given-names>K</given-names></string-name>, <string-name><surname>Stroick</surname><given-names>M</given-names></string-name>, <string-name><surname>Bertsch</surname><given-names>T</given-names></string-name>, et al. <article-title>Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide</article-title>. <source>Neurology</source>
<year>2002</year>;<volume>59</volume>(<issue>8</issue>):<fpage>1257</fpage>–<lpage>1258</lpage>.<pub-id pub-id-type="pmid">12391360</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0043"><string-name><surname>Locatelli</surname><given-names>S</given-names></string-name>, <string-name><surname>Lütjohann</surname><given-names>D</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>HH‐J</given-names></string-name>, et al. <article-title>Reduction of plasma 24S‐hydroxycholesterol (cerebrosterol) levels using high‐dosage simvastatin in patients with hypercholesterolemia</article-title>. <source>Arch Neurol‐chicago</source>
<year>2002</year>;<volume>59</volume>(<issue>2</issue>):<fpage>213</fpage>.<pub-id pub-id-type="pmid">11843691</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0044"><string-name><surname>Serrano‐Pozo</surname><given-names>A</given-names></string-name>, <string-name><surname>Vega</surname><given-names>GL</given-names></string-name>, <string-name><surname>Lütjohann</surname><given-names>D</given-names></string-name>, et al. <article-title>Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers</article-title>. <source>Alzheimer Dis Assoc Disord</source>
<year>2010</year>;<volume>24</volume>(<issue>3</issue>):<fpage>220</fpage>–<lpage>226</lpage>.<pub-id pub-id-type="pmid">20473136</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0045"><string-name><surname>Evans</surname><given-names>BA</given-names></string-name>, <string-name><surname>Evans</surname><given-names>JE</given-names></string-name>, <string-name><surname>Baker</surname><given-names>SP</given-names></string-name>, et al. <article-title>Long‐term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease</article-title>. <source>Dement Geriatr Cogn</source>
<year>2009</year>;<volume>27</volume>(<issue>6</issue>):<fpage>519</fpage>–<lpage>524</lpage>.</mixed-citation>
              </ref>
              <ref id="acn351421-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0046"><string-name><surname>Wood</surname><given-names>WG</given-names></string-name>, <string-name><surname>Eckert</surname><given-names>GP</given-names></string-name>, <string-name><surname>Igbavboa</surname><given-names>U</given-names></string-name>, <string-name><surname>Müller</surname><given-names>WE</given-names></string-name>. <article-title>Statins and neuroprotection</article-title>. <source>Ann Ny Acad Sci</source><year>2010</year>;<volume>1199</volume>(<issue>1</issue>):<fpage>69</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">20633110</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0047"><string-name><surname>Eckert</surname><given-names>GP</given-names></string-name>, <string-name><surname>Hooff</surname><given-names>GP</given-names></string-name>, <string-name><surname>Strandjord</surname><given-names>DM</given-names></string-name>, et al. <article-title>Regulation of the brain isoprenoids farnesyl‐ and geranylgeranylpyrophosphate is altered in male Alzheimer patients</article-title>. <source>Neurobiol Dis</source>
<year>2009</year>;<volume>35</volume>(<issue>2</issue>):<fpage>251</fpage>–<lpage>257</lpage>.<pub-id pub-id-type="pmid">19464372</pub-id></mixed-citation>
              </ref>
              <ref id="acn351421-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0048"><string-name><surname>McGuinness</surname><given-names>B</given-names></string-name>, <string-name><surname>Craig</surname><given-names>D</given-names></string-name>, <string-name><surname>Bullock</surname><given-names>R</given-names></string-name>, et al. <article-title>Statins for the treatment of dementia</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2014</year>;<volume>7</volume>(<issue>7</issue>):<fpage>CD007514</fpage>.</mixed-citation>
              </ref>
              <ref id="acn351421-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="acn351421-cit-0049"><string-name><surname>Geifman</surname><given-names>N</given-names></string-name>, <string-name><surname>Brinton</surname><given-names>RD</given-names></string-name>, <string-name><surname>Kennedy</surname><given-names>RE</given-names></string-name>, et al. <article-title>Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease</article-title>. <source>Alzheimer’s Res Ther</source>
<year>2017</year>;<volume>9</volume>(<issue>1</issue>):<fpage>10</fpage>.<pub-id pub-id-type="pmid">28212683</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
